Table 2.

Characteristics in patients with known primary cancer and categorisation by primary cancer type

Parameters	Findings	Adrenal metastasis
		All patients with known primary cancer (n=229)			Patients with lung cancer (n=103)			Patients with gastrointestinal cancer (n=31)			Patients with liver cancer (n=25)
		Yes (n=151)	No (n=78)	p-value	Yes (n=79)	No (n=24)	p-value	Yes (n=13)	No (n=18)	p-value	Yes (n=12)	No (n=13)	p-value
Age (years)		54.8±12.5	65.5±11.7	0.028	59.2±13.0	62.4±11.7	0.090	56.1±12.7	64.8±10.4	0.010	60.4±9.9	57.3±11.2	0.160
Left adrenal	Nodule or mass	76 (50.3%)	24 (30.7%)	0.003	36 (45.5%)	8 (33.3%)	0.125	6 (46.1%)	7 (38.8%)	0.381	5 (41.6%)	7 (53.8%)	0.580
Right adrenal	Nodule or mass	49 (32.4%)	11 (14.1%)	0.009	19 (24.0%)	5 (20.8%)	0.430	4 (30.7%)	5 (27.7%)	0.600	5 (41.6%)	9 (69.2%)	0.057
Unenhanced	≤10 HU	11 (8.8%)	31 (89.9%)	0.001	5 (9.0%)	10 (76.9%)	0.009	2 (20.0%)	11 (91.6%)		0	5
Attenuation	>10 HU	114 (91.2%)	4 (11.1%)	0.001	50 (91.0%)	3 (23.1%)	0.010	8 (80.0%)	1(8.4%)		6	0
SUVmax ratio	≤2.5	68 (45.0%)	41 (52.5%)		29 (36.7%)	5 (20.8%)		8 (61.5%)	6 (33.3%)		0 (0.0%)	0 (0.0%)
	>2.5	50 (33.1%)	2 (2.1%)		32 (40.5%)	1 (4.1%)		5 (38.4%)	0 (0.0%)		6 (50.0%)	5 (38.4%)
	No 18F-FDG uptake	9 (5.9%)	59 (75.6%)	<0.001	3 (3.7%)	15 (62.5%)	<0.001	1 (7.6%)	11 (61.8%)	<0.001	1 (8.3%)	7 (53.8%)	<0.001
Metastasis in other parts	Yes	121 (73.5%)	24 (29.4%)	<0.001	62 (74.6%)	9 (29.1%)	<0.001	11 (84.6%)	9 (50.0%)	0.008	8 (58.3%)	4 (23.0%)	0.214
	No	30 (13.2%)	54 (66.6%)		17 (18.9%)	15 (54.1%)		2 (15.3%)	9 (50.0%)		4 (0.25%)	9 (61.5%)
Primary	Lung cancer	77 (49.0%)	26 (37.1%)	0.002
	Gastrointestinal cancer	15 (7.9%)	16 (24.3%)	0.014
	Liver cancer	13 (7.2%)	12 (17.9%)	0.174
	Other	46 (28.4%)	24 (34.6%)	0.156

¹⁸F-FDG, flourine-18 fludeoxyglucose; SUV_max, maximum standardised uptake value.